President's Message by Howard, L
physician.
• While healthcare professionals appear to use current guidelines,
“polypharmacy” [use of more than one medication from the
same class to achieve the same result] exists.
• Multiple routes of administration are common in acute care
settings. These tend to reduce the patients’ understanding of their
pain medications and to increase costs.
Patient identified barriers to effective pain relief are:
1. Failure of caregivers to believe complaints of pain.
2. Fear of addiction.
3. Undesirable side effects.
5. High costs of opiates.
5. Delay in response to requests to nurses for medication.
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This issue contains two manuscripts related to psychiatry. It is
not one of our “Special Issues,” but does have information about care
of psychiatric patients and should be of interest to all physicians.
Mahalo to Anders and Olson and to Patrick and associates for
important data for Hawaii’s psychiatric care givers and administra
tors.
There is also a perception that many physicians, who have the
greatest responsibility for pain management, have a less than opti
mal understanding of pain control. They have unreasonable con
cerns regarding the activities of the Drug Enforcement Administra
tion [DEA], fear of lethal side effects and often underestimate the
impact of pain on the lives of their patients.
Several health care institutions in the State of Hawaii have
instituted pain management programs that have improved pain
management in those institutions. This suggests that requiring pain
management programs in health care institutions would have a
major impact on the lives of patients receiving care in those institu
tions.
Including pain management as an educational requirement in all
health care professional training and continuing education programs
would also be of significant benefit.
We Recommend
1. That the Agency for Healthcare Policy and Research [AHCPR]
guidelines for the treatment of pain be accepted as the commu
nity standard of care for all health care providers.
2. That a right to skilled pain management be included in a “Patients
Bill of Rights” at all Department of Health certified and/or
licensed facilities.3
3. That pain management programs be instituted in each of those
facilities.
4. That the AHCPR guidelines be accepted as practice standards in
each of those facilities.
5. That educational course work in pain management be a required
part of continuing education programs of licensed facilities.
6. That the Department of Health licensing and certification teams
specifically include pain management when reviewing records,
observing patientlclient care, interviewing staff and clients, etc.,
in their overall review of patient care plans/management.
7. That the Department of Health cite any institution that it finds
deficient in the areas noted above.
8. That pain management be part of the required curriculum of all
medical, nursing and other health care professional schools in the
State of Hawaii.
9. That professional organizations be challenged to adopt formally
AHCPR standards and incorporate them in their peer review and
continuing education programs.
President’s Message
Leonard Howard MD
President, Hawaii Medical Association
The Governor’s Blue Ribbon Committee on Living and Dying has
submitted their report after 18 months of work. The majority of the
committee urges the Governor to support any legislation allowing
Physician Assisted Suicide (PAS) and/or Physician Assisted Death
(PAD). A dissenting minority report was also submitted opposing
the same. This, plus the special edition of the Hawaii Medical
Journal, which was criticized by many members as indicating that
the HMA supported PAS and PAD, has stimulated this personal
opinion.
Your Hawaii Medical Association continues to support the AMA
policy opposing both PAS and PAD. We support the efforts to
improve pain management and end-of-life care to eliminate the
horror stories of terminal suffering that we have all heard. The lead
article in AMNews of November 15, 1996 said it very well:
“Although for some patients it might appear compassionate to
intentionally cause death, institutionalizing physician-assisted sui
cide as a medical treatment wouldput many morepatients at serious
riskfor unwanted and unnecessary death, “ they said. “Rather than
recognize a right to physician-assisted suicide, our society’ instead
should recognize the urgent necessity ofextending to allpatients the
palliative care they need and redouble our efforts to provide such
care to all.” The AMA also submitted an amicus brief to the US
Supreme Court when it was considering the issue of PAS in regard
to the Oregon initiative. The AMA brief begins by affirming that:
“The right to control one ‘s medical treatment is among the most
important rights that the law affords each person. “This includes the
right to have unwanted life-prolonging treatment withheld or with
drawn and to have all medication necessary to alleviate physical
pain, even where such medication would hasten death. Through
these means, patients can avoid entrapment in a prolonged, pairful,
or overly medicalized dying process.” The AMA believes firmly
that the lower court was wrong in taking the unprecedented step of
announcing a right to control the timing and manner of one’s death
through the use of physician-assisted suicide. The power to assist in
intentionally taking the life of a patient is counter to the health care
profession’s central mission of healing, It is a power that most health
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care professionals do not want and could not
control. The brief concludes that “The senti
ment for physician-assisted suicide is not the
right answer to the problem ofinadequate care.
Although for some patients it might appear
compassionate to hasten death, institutionaliz
ingphysician-assistedsuicideasa medical treat
ment would put many more patients at serious
risk for unwanted and unnecessary death.
Rather than recognize a right to physician-as
sisted suicide, the AMA asserts that “we should
recognize instead the urgent necessity of ex
tending to all patients the palliative care they
need and redouble our efforts to provide such
care to all.”
At an Intensive Seminar in Bioethics spon
sored by the Bioethics Consultation Group, Inc.
of Berkeley, California, a full day was spent on
Decisions at the End of Life. A message from
that day stuck in my mind, and I have quoted it
many times since hearing it. “The difference
between withholding Nutrition and Lethal In
jection is the difference between letting die and
killing.” To me this is the essence of the debate.
Will we overthrow the teachings of the philoso
phers of the last 2000 years or will we hew to
some new idea that physicians are to be the
instrument by which an individual chooses to
end his or her life? As for me, I will continue to
support the concept that physicians preserve life
as long as possible, but prevent suffering. If, by
giving a dose of MS adequate to relieve pain I
cause respiratory failure, then so be it. The
patient’s disease has been the essential reason
for the death, not my action. On the other hand,
if I inject a lethal
